BACKGROUND: In Gipuzkoa, screening for breast cancer was initiated in 1997 and in this paper we present breast cancer characteristics and survival for women diagnosed during the pre-screening period. METHODS: All cases diagnosed during 1995-1996 were included and the tumour characteristics were analysed. One-, five- and ten-year observed and relative survival (RS) were estimated overall, as well as by age and tumour characteristics. Multiple regression models were used to evaluate the effect of tumour characteristics on ten-year RS. RESULTS: Six hundred and twenty-two cases with a mean age of 60.7+/-15 years were included. The mean follow-up was 7.5 years (max. 10) with a mortality of 40.5%. Ductal carcinoma accounted for 78% of all cases; almost 50% had good or moderate differentiation and 28% were positive for both hormone receptors studied. Nearly 80% of cases were diagnosed in stage I or II and breast-conserving surgery was employed more often than mastectomy. Age-standardised RS was 77% (95% CI 72.1-82.3) and 68% (95% CI 60.4-74.6), five and ten years after diagnosis respectively. The relative excess risk of death was significantly different only for age, stage and degree of differentiation. DISCUSSION: This study shows an increase in survival compared to previous studies in the region. This could be explained by advances in diagnosis and treatment, as demonstrated by younger age and earlier stage at diagnosis and by the therapy profiles. Age and stage were shown to be major predictors of survival in our study and adjustment for the other factors had only limited effects on the risk of death for these two variables.
BACKGROUND: In Gipuzkoa, screening for breast cancer was initiated in 1997 and in this paper we present breast cancer characteristics and survival for women diagnosed during the pre-screening period. METHODS: All cases diagnosed during 1995-1996 were included and the tumour characteristics were analysed. One-, five- and ten-year observed and relative survival (RS) were estimated overall, as well as by age and tumour characteristics. Multiple regression models were used to evaluate the effect of tumour characteristics on ten-year RS. RESULTS: Six hundred and twenty-two cases with a mean age of 60.7+/-15 years were included. The mean follow-up was 7.5 years (max. 10) with a mortality of 40.5%. Ductal carcinoma accounted for 78% of all cases; almost 50% had good or moderate differentiation and 28% were positive for both hormone receptors studied. Nearly 80% of cases were diagnosed in stage I or II and breast-conserving surgery was employed more often than mastectomy. Age-standardised RS was 77% (95% CI 72.1-82.3) and 68% (95% CI 60.4-74.6), five and ten years after diagnosis respectively. The relative excess risk of death was significantly different only for age, stage and degree of differentiation. DISCUSSION: This study shows an increase in survival compared to previous studies in the region. This could be explained by advances in diagnosis and treatment, as demonstrated by younger age and earlier stage at diagnosis and by the therapy profiles. Age and stage were shown to be major predictors of survival in our study and adjustment for the other factors had only limited effects on the risk of death for these two variables.
Authors: M Martín; E Mahillo; A Llombart-Cussac; A Lluch; B Munarriz; M Pastor; E Alba; A Ruiz; A Antón; B Bermejo Journal: Clin Transl Oncol Date: 2006-07 Impact factor: 3.405
Authors: Milena Sant; Claudia Allemani; Riccardo Capocaccia; Timo Hakulinen; Tiiu Aareleid; Jan Willem Coebergh; Michel P Coleman; Pascale Grosclaude; Carmen Martinez; Janine Bell; Judith Youngson; Franco Berrino Journal: Int J Cancer Date: 2003-09-01 Impact factor: 7.396
Authors: M Sant; R Capocaccia; A Verdecchia; J Estève; G Gatta; A Micheli; M P Coleman; F Berrino Journal: Int J Cancer Date: 1998-08-31 Impact factor: 7.396
Authors: Milena Sant; Claudia Allemani; Franco Berrino; Michel P Coleman; Tiiu Aareleid; Gilles Chaplain; Jan Willem Coebergh; Marc Colonna; Paolo Crosignani; Arlette Danzon; Massimo Federico; Lorenzo Gafà; Pascale Grosclaude; Guy Hédelin; Josette Macè-Lesech; Carmen Martinez Garcia; Henrik Møller; Eugenio Paci; Nicole Raverdy; Brigitte Tretarre; Evelyn M I Williams Journal: Cancer Date: 2004-02-15 Impact factor: 6.860
Authors: M Zorzi; D Puliti; M Vettorazzi; V De Lisi; F Falcini; M Federico; S Ferretti; I F Moffa; L Mangone; M P Mano; C Naldoni; A Ponti; A Traina; R Tumino; E Paci Journal: Br J Cancer Date: 2006-10-17 Impact factor: 7.640
Authors: C Allemani; M Sant; F Berrino; T Aareleid; G Chaplain; J W Coebergh; M Colonna; P Contiero; A Danzon; M Federico; L Gafà; P Grosclaude; G Hédelin; J Macè-Lesech; C M Garcia; E Paci; N Raverdy; B Tretarre; E M I Williams Journal: Br J Cancer Date: 2004-10-04 Impact factor: 7.640
Authors: Carlos Manuel Guerrero López; Jorge Alberto Jiménez Ruiz; Luz Myriam Reynales Shigematsu; Hugh R Waters Journal: Tob Control Date: 2011-02-03 Impact factor: 7.552
Authors: Ruth Puig-Peiro; Anne Mason; Jorge Mestre-Ferrandiz; Adrian Towse; Clare McGrath; Bengt Jonsson Journal: Int J Technol Assess Health Care Date: 2016-01-20 Impact factor: 2.188